Cynthia Firnhaber
Research Interests
Cynthia Firnhaber has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Quanbeck
Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States
2 shared publications - Cameron Liebert
School of Medicine and Public Health, University of Wisconsin-Madison, 610 Walnut Street, Madison, WI, 53726, United States, 1 6082632880
2 shared publications - Emily Steeley
Vivent Health, Denver, CO, United States
2 shared publications - Hailey K. Ballard
Department of Population Health Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, USA
2 shared publications - Kathryn Schnippel
Right to Care, Johannesburg, South Africa
2 shared publications - Linda Sujin Park
Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States
2 shared publications
Latest Publications
- 29 October 2025
- Published by Springer Nature in International Journal of Behavioral Medicine
- p. 1-13
Effect of Prevalent and Incident Comorbidity Diagnoses on Quit Attempts and Prescription of Smoking Cessation Medications, HIV Outpatient Study, 2007–2022
Background People with HIV (PWH) are more likely to smoke, have comorbidities, and be less likely to quit than the general population. This study aimed to describe the prescription of smoking cessation medications and quit smoking attempts, and to assess the effect of prevalent and incident comorbidity diagnoses on these two outcomes. Methods We analyzed the 2007–2022 HIV Outpatient Study (HOPS) medical records and self-reported risk behavior survey data. We included adult PWH with evidence of current cigarette use at enrollment (baseline) or incident cigarette use. Comorbidities were identified based on laboratory results, clinical diagnoses, and treatments. We assessed associations of time-updated (baseline and incident) comorbidity diagnosis with prescription of smoking cessation medications and first attempt to quit using Cox proportional hazards analyses. Results Among 1068 eligible participants followed over a median time of 3.1 years (interquartile range 1.2–6.8 years), 304 (29%) were prescribed smoking cessation medications. Multivariable factors positively associated with prescribed smoking cessation medications included year of first HOPS visit (adjusted hazard ratio (aHR) 1.09), having diagnoses of depression (aHR 1.39), or chronic obstructive pulmonary disease/emphysema (aHR 1.89). Among 464 people who smoked at baseline and had at least one ACASI survey, during a median follow-up time of 2.3 years (interquartile range 0.8–5.2 years), 163 (35%) attempted to quit smoking. Multivariable factors positively associated with first attempt to quit included year of first HOPS visit (aHR 1.24), having a diagnosis of depression (aHR 1.30) or bipolar disorder (aHR 1.62), and being prescribed smoking cessation medications (range aHR 2.62–aHR 5.97, depending on the medication), whereas having a diagnosis of psychosis (aHR 0.29), hypertension (aHR 0.41), or obesity (aHR 0.49) was inversely associated. Conclusion In the HOPS, about one-third of smokers were prescribed smoking cessation medications, and of those who completed the risk behavior survey, one-third attempted to quit. Among incident comorbidities examined, time-updated depression was both positively associated with being prescribed smoking cessation medications and attempting to quit smoking. Our results highlight the need for better integration of smoking cessation and prevention programs into PWH care.
- 29 October 2025
- Published by Springer Nature in International Journal of Behavioral Medicine
- p. 1-13
Effect of Prevalent and Incident Comorbidity Diagnoses on Quit Attempts and Prescription of Smoking Cessation Medications, HIV Outpatient Study, 2007–2022
Background People with HIV (PWH) are more likely to smoke, have comorbidities, and be less likely to quit than the general population. This study aimed to describe the prescription of smoking cessation medications and quit smoking attempts, and to assess the effect of prevalent and incident comorbidity diagnoses on these two outcomes. Methods We analyzed the 2007–2022 HIV Outpatient Study (HOPS) medical records and self-reported risk behavior survey data. We included adult PWH with evidence of current cigarette use at enrollment (baseline) or incident cigarette use. Comorbidities were identified based on laboratory results, clinical diagnoses, and treatments. We assessed associations of time-updated (baseline and incident) comorbidity diagnosis with prescription of smoking cessation medications and first attempt to quit using Cox proportional hazards analyses. Results Among 1068 eligible participants followed over a median time of 3.1 years (interquartile range 1.2–6.8 years), 304 (29%) were prescribed smoking cessation medications. Multivariable factors positively associated with prescribed smoking cessation medications included year of first HOPS visit (adjusted hazard ratio (aHR) 1.09), having diagnoses of depression (aHR 1.39), or chronic obstructive pulmonary disease/emphysema (aHR 1.89). Among 464 people who smoked at baseline and had at least one ACASI survey, during a median follow-up time of 2.3 years (interquartile range 0.8–5.2 years), 163 (35%) attempted to quit smoking. Multivariable factors positively associated with first attempt to quit included year of first HOPS visit (aHR 1.24), having a diagnosis of depression (aHR 1.30) or bipolar disorder (aHR 1.62), and being prescribed smoking cessation medications (range aHR 2.62–aHR 5.97, depending on the medication), whereas having a diagnosis of psychosis (aHR 0.29), hypertension (aHR 0.41), or obesity (aHR 0.49) was inversely associated. Conclusion In the HOPS, about one-third of smokers were prescribed smoking cessation medications, and of those who completed the risk behavior survey, one-third attempted to quit. Among incident comorbidities examined, time-updated depression was both positively associated with being prescribed smoking cessation medications and attempting to quit smoking. Our results highlight the need for better integration of smoking cessation and prevention programs into PWH care.
- Open Access
- 29 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e69842
Health System–Level Implementation of Digital Health Support for People Living With HIV and Substance Use Disorders: Protocol for a Cluster-Randomized, Stepped-Wedge Clinical Trial
Background: People living with HIV who are affected by substance use disorders and other social vulnerabilities are less likely to achieve and sustain viral suppression. Supporting these patients with mobile health systems can provide additional social and behavioral support that may improve HIV outcomes in these populations. Objective: This study aims to implement and evaluate an evidence-based digital health system (antiretroviral therapy care coordination; ART-C) to improve HIV viral suppression and reduce missed clinic visits within a multisite HIV care program. Methods: ART-C will be implemented in 8 HIV medical home clinics operated by Vivent Health in Colorado, Missouri, Texas, and Wisconsin. All patients receiving HIV care across the system will be invited to use a customized version of the Connections smartphone app to join a virtual community of peers living with HIV. A subset of patients with substance use disorder will be recruited to use enhanced features of the app, allowing sharing of information about substance use and other social determinants of health with their care team. Effectiveness and implementation outcomes will be evaluated using a stepped-wedge clinical trial design. Effectiveness will be evaluated by comparing missed visits and viral nonsuppression rates before and after the intervention. Implementation will be evaluated using a mixed methods approach based on the reach, effectiveness, adoption, implementation, and maintenance framework. Results: Funding was received April 2022 with data collection beginning December 6, 2023. Data collection is anticipated to end in 2027 with data analysis and results expected late 2027. As of submission of the manuscript, 86 participants were recruited. Of the 6710 patients with health record data available 2 years before the trial began, 1723 (25.68%) had a substance use disorder, 2825 (42.1%) missed at least 2 care visits, and 1354 (20.18%) had at least 1 detectable HIV RNA test (viral load ≥200 copies/mL), leaving 3816 (56.87%) eligible individuals. Analysis of preimplementation data demonstrated that patients had a mean of 4.1 (SD 2.1) to 7.8 (SD 5.5) care visits across all 8 Vivent Health sites, with 45% to 70% of patients missing at least 1 visit. Patients underwent a mean of 2.2 to 4 HIV RNA tests, and 14% to 37% of patients across clinics had at least 1 nonsuppressed HIV RNA result. Primary analyses are expected to be completed by 2028. Conclusions: This study will evaluate the effectiveness of and implementation strategies for a mobile health–based intervention to support patients with HIV, substance use disorder, and related challenges in engaging in care and achieving viral suppression. International Registered Report Identifier (IRRID): DERR1-10.2196/69842
- 29 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e69842
Open AccessHealth System–Level Implementation of Digital Health Support for People Living With HIV and Substance Use Disorders: Protocol for a Cluster-Randomized, Stepped-Wedge Clinical Trial
Background: People living with HIV who are affected by substance use disorders and other social vulnerabilities are less likely to achieve and sustain viral suppression. Supporting these patients with mobile health systems can provide additional social and behavioral support that may improve HIV outcomes in these populations. Objective: This study aims to implement and evaluate an evidence-based digital health system (antiretroviral therapy care coordination; ART-C) to improve HIV viral suppression and reduce missed clinic visits within a multisite HIV care program. Methods: ART-C will be implemented in 8 HIV medical home clinics operated by Vivent Health in Colorado, Missouri, Texas, and Wisconsin. All patients receiving HIV care across the system will be invited to use a customized version of the Connections smartphone app to join a virtual community of peers living with HIV. A subset of patients with substance use disorder will be recruited to use enhanced features of the app, allowing sharing of information about substance use and other social determinants of health with their care team. Effectiveness and implementation outcomes will be evaluated using a stepped-wedge clinical trial design. Effectiveness will be evaluated by comparing missed visits and viral nonsuppression rates before and after the intervention. Implementation will be evaluated using a mixed methods approach based on the reach, effectiveness, adoption, implementation, and maintenance framework. Results: Funding was received April 2022 with data collection beginning December 6, 2023. Data collection is anticipated to end in 2027 with data analysis and results expected late 2027. As of submission of the manuscript, 86 participants were recruited. Of the 6710 patients with health record data available 2 years before the trial began, 1723 (25.68%) had a substance use disorder, 2825 (42.1%) missed at least 2 care visits, and 1354 (20.18%) had at least 1 detectable HIV RNA test (viral load ≥200 copies/mL), leaving 3816 (56.87%) eligible individuals. Analysis of preimplementation data demonstrated that patients had a mean of 4.1 (SD 2.1) to 7.8 (SD 5.5) care visits across all 8 Vivent Health sites, with 45% to 70% of patients missing at least 1 visit. Patients underwent a mean of 2.2 to 4 HIV RNA tests, and 14% to 37% of patients across clinics had at least 1 nonsuppressed HIV RNA result. Primary analyses are expected to be completed by 2028. Conclusions: This study will evaluate the effectiveness of and implementation strategies for a mobile health–based intervention to support patients with HIV, substance use disorder, and related challenges in engaging in care and achieving viral suppression. International Registered Report Identifier (IRRID): DERR1-10.2196/69842
- Open Access
- 23 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Health System–Level Implementation of Digital Health Support for People Living With HIV and Substance Use Disorders: Protocol for a Cluster-Randomized, Stepped-Wedge Clinical Trial (Preprint)
BACKGROUND People living with HIV who are affected by substance use disorders and other social vulnerabilities are less likely to achieve and sustain viral suppression. Supporting these patients with mobile health systems can provide additional social and behavioral support that may improve HIV outcomes in these populations. OBJECTIVE This study aims to implement and evaluate an evidence-based digital health system (antiretroviral therapy care coordination; ART-C) to improve HIV viral suppression and reduce missed clinic visits within a multisite HIV care program. METHODS ART-C will be implemented in 8 HIV medical home clinics operated by Vivent Health in Colorado, Missouri, Texas, and Wisconsin. All patients receiving HIV care across the system will be invited to use a customized version of the Connections smartphone app to join a virtual community of peers living with HIV. A subset of patients with substance use disorder will be recruited to use enhanced features of the app, allowing sharing of information about substance use and other social determinants of health with their care team. Effectiveness and implementation outcomes will be evaluated using a stepped-wedge clinical trial design. Effectiveness will be evaluated by comparing missed visits and viral nonsuppression rates before and after the intervention. Implementation will be evaluated using a mixed methods approach based on the reach, effectiveness, adoption, implementation, and maintenance framework. RESULTS Funding was received April 2022 with data collection beginning December 6, 2023. Data collection is anticipated to end in 2027 with data analysis and results expected late 2027. As of submission of the manuscript, 86 participants were recruited. Of the 6710 patients with health record data available 2 years before the trial began, 1723 (25.68%) had a substance use disorder, 2825 (42.1%) missed at least 2 care visits, and 1354 (20.18%) had at least 1 detectable HIV RNA test (viral load ≥200 copies/mL), leaving 3816 (56.87%) eligible individuals. Analysis of preimplementation data demonstrated that patients had a mean of 4.1 (SD 2.1) to 7.8 (SD 5.5) care visits across all 8 Vivent Health sites, with 45% to 70% of patients missing at least 1 visit. Patients underwent a mean of 2.2 to 4 HIV RNA tests, and 14% to 37% of patients across clinics had at least 1 nonsuppressed HIV RNA result. Primary analyses are expected to be completed by 2028. CONCLUSIONS This study will evaluate the effectiveness of and implementation strategies for a mobile health–based intervention to support patients with HIV, substance use disorder, and related challenges in engaging in care and achieving viral suppression. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/69842
- 23 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHealth System–Level Implementation of Digital Health Support for People Living With HIV and Substance Use Disorders: Protocol for a Cluster-Randomized, Stepped-Wedge Clinical Trial (Preprint)
BACKGROUND People living with HIV who are affected by substance use disorders and other social vulnerabilities are less likely to achieve and sustain viral suppression. Supporting these patients with mobile health systems can provide additional social and behavioral support that may improve HIV outcomes in these populations. OBJECTIVE This study aims to implement and evaluate an evidence-based digital health system (antiretroviral therapy care coordination; ART-C) to improve HIV viral suppression and reduce missed clinic visits within a multisite HIV care program. METHODS ART-C will be implemented in 8 HIV medical home clinics operated by Vivent Health in Colorado, Missouri, Texas, and Wisconsin. All patients receiving HIV care across the system will be invited to use a customized version of the Connections smartphone app to join a virtual community of peers living with HIV. A subset of patients with substance use disorder will be recruited to use enhanced features of the app, allowing sharing of information about substance use and other social determinants of health with their care team. Effectiveness and implementation outcomes will be evaluated using a stepped-wedge clinical trial design. Effectiveness will be evaluated by comparing missed visits and viral nonsuppression rates before and after the intervention. Implementation will be evaluated using a mixed methods approach based on the reach, effectiveness, adoption, implementation, and maintenance framework. RESULTS Funding was received April 2022 with data collection beginning December 6, 2023. Data collection is anticipated to end in 2027 with data analysis and results expected late 2027. As of submission of the manuscript, 86 participants were recruited. Of the 6710 patients with health record data available 2 years before the trial began, 1723 (25.68%) had a substance use disorder, 2825 (42.1%) missed at least 2 care visits, and 1354 (20.18%) had at least 1 detectable HIV RNA test (viral load ≥200 copies/mL), leaving 3816 (56.87%) eligible individuals. Analysis of preimplementation data demonstrated that patients had a mean of 4.1 (SD 2.1) to 7.8 (SD 5.5) care visits across all 8 Vivent Health sites, with 45% to 70% of patients missing at least 1 visit. Patients underwent a mean of 2.2 to 4 HIV RNA tests, and 14% to 37% of patients across clinics had at least 1 nonsuppressed HIV RNA result. Primary analyses are expected to be completed by 2028. CONCLUSIONS This study will evaluate the effectiveness of and implementation strategies for a mobile health–based intervention to support patients with HIV, substance use disorder, and related challenges in engaging in care and achieving viral suppression. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/69842
- 1 April 2024
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 38  (4) , 151-154
Mammogram and Pap Smear Uptake Among Women in the HIV Outpatient Study USA, 2010–2021
- 1 April 2024
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 38  (4) , 151-154
Mammogram and Pap Smear Uptake Among Women in the HIV Outpatient Study USA, 2010–2021
- Open Access
- 25 September 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73  (7) , e2211-e2216
Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus: A Randomized, Double-blind, Placebo-controlled Trial
Women living with human immunodeficiency virus (HIV), especially in sub-Saharan Africa, are at high risk for cervical high-grade squamous intraepithelial lesions (HSIL) and cervical cancer. These women have high HSIL recurrence rates after loop electroexcision procedure (LEEP). Retrospective studies suggest that human papillomavirus (HPV) vaccination improves response to treatment of cervical HSIL. We performed a double-blind, randomized clinical trial enrolling 180 women living with HIV in Johannesburg, South Africa, diagnosed with cervical HSIL by colposcopic biopsy. Women received quadrivalent HPV vaccine or placebo (1:1) at entry, week 4, and week 26. LEEP was performed at week 4. Colposcopic-directed biopsies and cervical cytology were performed at weeks 26 and 52. The primary endpoint, cervical HSIL by histology or cytology at either week 26 or 52, was compared between arms using χ 2 analysis. Participant characteristics included median age of 39 years and median CD4 count 489 cells/μL, and 94% had HIV suppression. One hundred seventy-four women completed the vaccine/placebo series and had evaluable results at week 26 or 52. The proportion experiencing the primary endpoint was similar in the vaccine and placebo groups (53% vs 45%; relative risk, 1.18 [95% confidence interval, .87–1.6]; P = .29). HSIL recurrence was associated with a LEEP biopsy result of HSIL and detection of HSIL at the margins of the LEEP sample. This study did not support HPV vaccination to prevent recurrent HSIL after LEEP in women living with HIV. Recurrent HSIL was high despite virologic suppression. Improved treatments are needed for HSIL to reduce the burden of cervical cancer among women living with HIV. NCT01928225.
- 25 September 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73  (7) , e2211-e2216
Open AccessHuman Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus: A Randomized, Double-blind, Placebo-controlled Trial
Women living with human immunodeficiency virus (HIV), especially in sub-Saharan Africa, are at high risk for cervical high-grade squamous intraepithelial lesions (HSIL) and cervical cancer. These women have high HSIL recurrence rates after loop electroexcision procedure (LEEP). Retrospective studies suggest that human papillomavirus (HPV) vaccination improves response to treatment of cervical HSIL. We performed a double-blind, randomized clinical trial enrolling 180 women living with HIV in Johannesburg, South Africa, diagnosed with cervical HSIL by colposcopic biopsy. Women received quadrivalent HPV vaccine or placebo (1:1) at entry, week 4, and week 26. LEEP was performed at week 4. Colposcopic-directed biopsies and cervical cytology were performed at weeks 26 and 52. The primary endpoint, cervical HSIL by histology or cytology at either week 26 or 52, was compared between arms using χ 2 analysis. Participant characteristics included median age of 39 years and median CD4 count 489 cells/μL, and 94% had HIV suppression. One hundred seventy-four women completed the vaccine/placebo series and had evaluable results at week 26 or 52. The proportion experiencing the primary endpoint was similar in the vaccine and placebo groups (53% vs 45%; relative risk, 1.18 [95% confidence interval, .87–1.6]; P = .29). HSIL recurrence was associated with a LEEP biopsy result of HSIL and detection of HSIL at the margins of the LEEP sample. This study did not support HPV vaccination to prevent recurrent HSIL after LEEP in women living with HIV. Recurrent HSIL was high despite virologic suppression. Improved treatments are needed for HSIL to reduce the burden of cervical cancer among women living with HIV. NCT01928225.
- Open Access
- 23 January 2019
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 20  (1) , 1017
Breast abnormalities in adolescents receiving antiretroviral therapy
Background: Antiretrovirals, particularly efavirenz (EFV), have been shown to cause breast abnormalities in adults. Little is known about the prevalence of these adverse effects among adolescents receiving antiretroviral therapy (ART).Objectives: The aim of this article was to examine the extent of breast abnormalities in adolescents receiving ART and determine any clinical associations.Methods: A retrospective record review describing breast conditions in adolescents receiving ART at three facilities in Johannesburg was conducted. Patients aged 10–19 years, who presented from January to December 2014, were included in the study. Analyses were conducted to determine whether EFV was associated with increased breast conditions.Results: Of the 631 patient records reviewed, 37 (6%) had an abnormal breast event documented; with 24/37 (65%) being male patients. Patients with abnormal breast conditions were 1.5 years older than patients with normal breast development (p 0.0005). Forty-one abnormal breast events were observed in 37 patients, with 20 described as gynaecomastia or lipomastia (49%). Of the 37 patients, 44% (n = 19) had concurrent generalised lipodystrophy. Of those with an abnormal breast event, 71% of patients had CD4 counts 500 cells/µL and were virologically suppressed (n = 29). Those on EFV had a significantly higher prevalence of breast abnormalities compared to other regimens (p = 0.016).Conclusion: Of the studied patients, 6% had an abnormal breast condition. The use of EFV and increased age were associated with breast abnormalities in this population. Further research is needed to better understand the implications of this potential side effect.
- 23 January 2019
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 20  (1) , 1017
Open AccessBreast abnormalities in adolescents receiving antiretroviral therapy
Background: Antiretrovirals, particularly efavirenz (EFV), have been shown to cause breast abnormalities in adults. Little is known about the prevalence of these adverse effects among adolescents receiving antiretroviral therapy (ART).Objectives: The aim of this article was to examine the extent of breast abnormalities in adolescents receiving ART and determine any clinical associations.Methods: A retrospective record review describing breast conditions in adolescents receiving ART at three facilities in Johannesburg was conducted. Patients aged 10–19 years, who presented from January to December 2014, were included in the study. Analyses were conducted to determine whether EFV was associated with increased breast conditions.Results: Of the 631 patient records reviewed, 37 (6%) had an abnormal breast event documented; with 24/37 (65%) being male patients. Patients with abnormal breast conditions were 1.5 years older than patients with normal breast development (p 0.0005). Forty-one abnormal breast events were observed in 37 patients, with 20 described as gynaecomastia or lipomastia (49%). Of the 37 patients, 44% (n = 19) had concurrent generalised lipodystrophy. Of those with an abnormal breast event, 71% of patients had CD4 counts 500 cells/µL and were virologically suppressed (n = 29). Those on EFV had a significantly higher prevalence of breast abnormalities compared to other regimens (p = 0.016).Conclusion: Of the studied patients, 6% had an abnormal breast condition. The use of EFV and increased age were associated with breast abnormalities in this population. Further research is needed to better understand the implications of this potential side effect.
- Open Access
- 1 October 2018
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 79  (2) , 195-205
Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study
Background: Women with HIV face an increased risk of human papillomavirus (HPV) acquisition and persistence, cervical intraepithelial neoplasia, and invasive cervical cancer. Our objective was to determine the cost-effectiveness of different cervical cancer screening strategies among women with HIV in South Africa.Methods: We modified a mathematical model of HPV infection and cervical disease to reflect coinfection with HIV. The model was calibrated to epidemiologic data from HIV-infected women in South Africa. Clinical and economic data were drawn from in-country data sources. The model was used to project reductions in the lifetime risk of cervical cancer and incremental cost-effectiveness ratios (ICERs) of Pap and HPV DNA screening and management algorithms beginning at HIV diagnosis, at 1-, 2-, or 3-year intervals. Strategies with an ICER below South Africa's 2016 per capita gross domestic product (US$5270) were considered “cost-effective.”Results: HPV testing followed by treatment (test-and-treat) at 2-year intervals was the most effective strategy that was also cost-effective, reducing lifetime cancer risk by 56.6% with an ICER of US$3010 per year of life saved. Other cost-effective strategies included Pap (referral threshold: HSIL+) at 1-, 2-, and 3-year intervals, and HPV test-and-treat at 3-year intervals. Pap (ASCUS+), HPV testing with 16/18 genotyping, and HPV testing with Pap or visual triage of HPV-positive women were less effective and more costly than alternatives.Conclusions: Considering per capita gross domestic product as the benchmark for cost-effectiveness, HPV test-and-treat is optimal in South Africa. At lower cost-effectiveness benchmarks, Pap (HSIL+) would be optimal.
- 1 October 2018
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 79  (2) , 195-205
Open AccessCost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study
Background: Women with HIV face an increased risk of human papillomavirus (HPV) acquisition and persistence, cervical intraepithelial neoplasia, and invasive cervical cancer. Our objective was to determine the cost-effectiveness of different cervical cancer screening strategies among women with HIV in South Africa.Methods: We modified a mathematical model of HPV infection and cervical disease to reflect coinfection with HIV. The model was calibrated to epidemiologic data from HIV-infected women in South Africa. Clinical and economic data were drawn from in-country data sources. The model was used to project reductions in the lifetime risk of cervical cancer and incremental cost-effectiveness ratios (ICERs) of Pap and HPV DNA screening and management algorithms beginning at HIV diagnosis, at 1-, 2-, or 3-year intervals. Strategies with an ICER below South Africa's 2016 per capita gross domestic product (US$5270) were considered “cost-effective.”Results: HPV testing followed by treatment (test-and-treat) at 2-year intervals was the most effective strategy that was also cost-effective, reducing lifetime cancer risk by 56.6% with an ICER of US$3010 per year of life saved. Other cost-effective strategies included Pap (referral threshold: HSIL+) at 1-, 2-, and 3-year intervals, and HPV test-and-treat at 3-year intervals. Pap (ASCUS+), HPV testing with 16/18 genotyping, and HPV testing with Pap or visual triage of HPV-positive women were less effective and more costly than alternatives.Conclusions: Considering per capita gross domestic product as the benchmark for cost-effectiveness, HPV test-and-treat is optimal in South Africa. At lower cost-effectiveness benchmarks, Pap (HSIL+) would be optimal.
- Open Access
- 1 May 2018
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 29  (3) , 371-382
Age Differences by Sex in Antiretroviral-NaĂŻve Participants: Pooled Analysis from Randomized Clinical Trials
Age and sex effects on antiretroviral therapy (ART) response are not well elucidated. Our pooled analysis of 40 randomized clinical trials measured the association of age and sex on CD4+ T cell count changes and virologic suppression using multivariable regression modeling. The average increase in CD4+ T cell count from baseline to week 48 was 17.3 cells/mm3 lower and clinically insignificant (95% confidence interval -30.8 to -3.8) among women ages ≥ 50 years (n = 573), compared to women ≤ 35 years (n = 3,939). Results were similar for men. Virologic suppression odds were 60% and 21% times greater among participants ≥50 years compared to ≤35 years, in women and men, respectively. In both sexes, larger increases in CD4+ T cell count changes were observed in younger, compared to older, participants; however, virologic suppression was higher in older, compared to younger, participants suggesting a non-sex-specific age effect response to ART.
- 1 May 2018
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 29  (3) , 371-382
Open AccessAge Differences by Sex in Antiretroviral-NaĂŻve Participants: Pooled Analysis from Randomized Clinical Trials
Age and sex effects on antiretroviral therapy (ART) response are not well elucidated. Our pooled analysis of 40 randomized clinical trials measured the association of age and sex on CD4+ T cell count changes and virologic suppression using multivariable regression modeling. The average increase in CD4+ T cell count from baseline to week 48 was 17.3 cells/mm3 lower and clinically insignificant (95% confidence interval -30.8 to -3.8) among women ages ≥ 50 years (n = 573), compared to women ≤ 35 years (n = 3,939). Results were similar for men. Virologic suppression odds were 60% and 21% times greater among participants ≥50 years compared to ≤35 years, in women and men, respectively. In both sexes, larger increases in CD4+ T cell count changes were observed in younger, compared to older, participants; however, virologic suppression was higher in older, compared to younger, participants suggesting a non-sex-specific age effect response to ART.